资金流向方面，今日主力资金净流入的科创板股共有219只，其中，6只个股主力资金净流入超3000万 元，芯原股份主力资金净流入9530.11万元，净流入资金居首；财富趋势、大地熊紧随其后，全天净流 入资金分别为6264.27万元、4807.96万元。主力资金净流出的有366只，净流出资金最多的是恒玄科技， 该股今日下跌5.00%，全天主力资金净流出1.43亿元，其次是寒武纪、澜起科技，主力资金净流出分别 为9631.09万元、5655.58万元。 从主力资金连续性进行观察，共有55只个股主力资金连续3个交易日以上持续净流入，连续流入天数最 多的是迅捷兴，该股已连续11个交易日净流入；连续净流入天数较多的还有耐科装备、利扬芯片等，主 力资金分别连续流入10天、8天。主力资金连续流出的个股有132只，连续流出天数最多的是先锋精科， 该股已连续20个交易日净流出；连续净流出天数较多的还有莱特光电、三达膜等，主力资金分别连续流 出13天、10天。（数据宝） 主力资金净流入排名 | 代码 | 简称 | 主力资金净流入（万元） | 主力资金流入率（%） | 涨跌幅（%） | 换手率（%） | | --- | --- | - ...

Core Viewpoint - The ongoing legal dispute between two listed companies in Shaanxi, SanDa Membrane and Blue Sky Technology, centers around a contract worth 58.61 million yuan related to lithium extraction equipment, with a recent court ruling requiring SanDa Membrane to pay 48.29 million yuan to Blue Sky Technology [1][10]. Group 1: Contractual Dispute - The conflict originated from a contract signed in March 2022 for the supply and installation of lithium extraction equipment, valued at 114 million yuan, as part of a larger project [4][7]. - SanDa Membrane claims that Blue Sky Technology failed to meet installation deadlines, leading to economic losses and justifying their counterclaim for 38.73 million yuan [4][7]. - The court ruled in favor of Blue Sky Technology, ordering SanDa Membrane to pay the specified amount and rejecting SanDa's counterclaims [5][10]. Group 2: Legal Proceedings - SanDa Membrane plans to appeal the first-instance ruling, indicating that the legal battle may continue into a second trial [2][10]. - The ongoing litigation has resulted in the freezing of 58.61 million yuan of SanDa Membrane's assets, impacting its financial operations [4][12]. Group 3: Financial Impact - SanDa Membrane reported a significant decline in net cash flow from operating activities, down 78.38% year-on-year to 12.19 million yuan, attributed to the legal disputes and asset freezes [17]. - The company has also faced additional arbitration related to another project, further complicating its financial situation [12][16]. Group 4: Broader Context - Both companies are experiencing multiple legal challenges, with Blue Sky Technology also facing a lawsuit for 53.5 million yuan from an insurance company related to an accident involving another party [20].

Group 1 - The sugar substitute concept declined by 0.82%, ranking among the top declines in the concept sector, with companies like Baolingbao, Bailong Chuangyuan, and Chenguang Biotech experiencing significant drops [1][2] - Among the sugar substitute stocks, 8 saw price increases, with Zhonghua International, Luxin Investment, and Xinghu Technology rising by 1.37%, 1.34%, and 1.09% respectively [1][2] - The sugar substitute sector experienced a net outflow of 118 million yuan, with 17 stocks seeing net outflows, and 5 stocks with outflows exceeding 10 million yuan, led by Jinhai Biological with a net outflow of 44.98 million yuan [2][3] Group 2 - The top net inflow stocks in the sugar substitute sector included Jinhai Industrial, Rhine Biological, and Shengquan Group, with net inflows of 16.36 million yuan, 12.29 million yuan, and 5.05 million yuan respectively [2][3] - The outflow leaderboard for the sugar substitute sector featured Jinhai Biological, Yasheng Group, and Baolingbao, with respective outflows of 44.98 million yuan, 25.20 million yuan, and 22.92 million yuan [2][3] - The trading activity in the sugar substitute sector showed varied turnover rates, with Baolingbao at 14.36% and Jinhai Biological at 6.48% [2][3]

活动时间：2025 年 5 月 20 日（星期二）15:00-17:00。 活动地址： "全景路演" 三达膜环境技术股份有限公司 关于参加"2025 年陕西辖区上市公司投资者集体接待日暨 2024 年度业绩说明会"的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 为促进上市公司规范运作、健康发展，增强上市公司信息透明度， 加强与广大投资者沟通交流，进一步提升投资者关系管理水平，陕西 上市公司协会根据陕西证监局工作部署，联合深圳市全景网络有限公 司举办"2025 年陕西辖区上市公司投资者集体接待日暨 2024 年度业 绩说明会"。 届时，公司总经理及相关高管人员将通过互动平台与投资者进行 网络沟通和交流。为充分尊重投资者、提升交流的针对性，现就公司 2024 年度业绩说明会提前向投资者公开征集问题，广泛听取投资者 的意见和建议。投资者可于 2025 年 5 月 19 日（星期一）16：00 前 访问"全景路演"（https://ir.p5w.net/zj），进入问题征集专题页 面。公司将在 2024 年度业绩说明会上 ...

关于重大诉讼的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： 案件所处的诉讼阶段：一审判决阶段 上市公司所处的当事人地位：上市公司为被告（反诉原告） 一 审 判 决 支 付 金 额 ： 一 审 判 决 本 公 司 支 付 人 民 币 48,286,889.21 元及逾期付款的违约金。 是否会对上市公司损益产生负面影响：本次判决为一审判决， 尚未生效执行。公司不服一审判决，将向上级人民法院进行上诉。本 次诉讼进展不会对公司日常生产经营产生重大不利影响，对公司本期 利润或期后利润的影响存在不确定性，最终实际影响以法院最终生效 判决结果为准。公司将根据本次诉讼事项的进展情况及时履行信息披 露义务，敬请广大投资者注意投资风险。 证券代码：688101 证券简称：三达膜 公告编号：2025-025 三达膜环境技术股份有限公司 公司向陕西省西安市雁塔区人民法院提交了《民事反诉状》，对 蓝晓科技在协议履行过程中的违约行为进行了反诉，并获得法院受理。 根据公司律师的反馈，2025 年 3 月 25 日该案双方当 ...

证券代码：688101 证券简称：三达膜 公告编号：2025-024 三达膜环境技术股份有限公司 关于公司与蓝晓科技合同纠纷案的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： 案件所处的诉讼阶段：一审判决阶段 上市公司所处的当事人地位：上市公司为被告（反诉原告） 一 审 判 决 支 付 金 额 ： 一 审 判 决 本 公 司 支 付 人 民 币 48,286,889.21 元及逾期付款的违约金。 是否会对上市公司损益产生负面影响：本次判决为一审判决， 尚未生效执行。公司不服一审判决，将向上级人民法院进行上诉。本 次诉讼进展不会对公司日常生产经营产生重大不利影响，对公司本期 利润或期后利润的影响存在不确定性，最终实际影响以法院最终生效 判决结果为准。公司将根据本次诉讼事项的进展情况及时履行信息披 露义务，敬请广大投资者注意投资风险。 一、本诉案件的基本情况 公司于 2025 年 3 月 6 日、3 月 7 日分别收到陕西省西安市雁塔 1 区人民法院寄送的《民事裁定书》《传票》，根据收到的法院文件显 ...

Core Insights - The behavior of margin traders has attracted significant market attention, with investors hoping to capture investment opportunities from their activities [1] Group 1: Margin Trading Data - On May 8, a total of 3,663 stocks received margin buying funds, with the top three stocks being Xinyi Technology (¥1.425 billion), Zhongji Xuchuang (¥1.053 billion), and Shenghong Technology (¥807 million) [1] - The table lists stocks with the highest margin buying amounts, including Tiancheng Technology (¥15.75 million), Xingqiu Graphite (¥8.83 million), and Lianyu Co. (¥15.27 million), showing their respective transaction amounts and margin buying ratios [1] - Margin buying accounted for significant percentages of total transaction amounts for various stocks, with Tiancheng Technology at 28.65%, Xingqiu Graphite at 28.51%, and Lianyu Co. at 28.15% [1] Group 2: Stock Performance - The price changes of stocks with high margin buying varied, with some stocks experiencing gains, such as Tiancheng Technology (1.47%) and Xingqiu Graphite (2.39%), while others like Fuliwang saw a decline (-3.29%) [1][2] - The data indicates that margin buying can correlate with stock performance, as seen in the fluctuations of the stocks listed [1][2]

证券代码：688101 证券简称：三达膜 三达膜环境技术股份有限公司 2024 年年度股东大会 会议资料 2025 年 5 月 三达膜环境技术股份有限公司 2024年年度股东大会会议资料 三达膜环境技术股份有限公司 2024 年年度股东大会资料目录 | 三达膜 2024 年年度股东大会会议须知 4 | | | --- | --- | | 三达膜 2024 年年度股东大会会议议程 6 | | | 三达膜 2024 年年度股东大会议案 | 8 | | 议案一：《关于洮南募投项目结项并将结余募集资金专户监管的议案》 | | | | 8 | | 议案二：《关于<2024 年年度报告及其摘要>的议案》 | 11 | | 议案三：《关于<2024 年度董事会工作报告>的议案》 | 12 | | 议案四：《关于<2024 年度监事会工作报告>的议案》 | 13 | | 议案五：《关于<2024 年度财务决算报告>的议案》 | 14 | | 议案六：《关于 2024 年度利润分配预案的议案》 | 15 | | 议案七：《关于董事、监事 2025 年度薪酬方案的议案》 | 17 | 2 三达膜环境技术股份有限公司 2024年年 ...

Financial Performance - Operating revenue for Q1 2025 was CNY 263,688,492.93, a decrease of 7.26% compared to the same period last year[4] - Net profit attributable to shareholders increased by 14.20% to CNY 76,224,948.98 from CNY 66,745,405.55 in the previous year[4] - Basic and diluted earnings per share rose by 15.00% to CNY 0.23[4] - Total operating revenue for Q1 2025 was ¥263.69 million, a decrease of 7.3% from ¥284.33 million in Q1 2024[19] - Net profit for Q1 2025 reached ¥77.83 million, an increase of 14.0% compared to ¥68.27 million in Q1 2024[20] - Basic and diluted earnings per share for Q1 2025 were both ¥0.23, up from ¥0.20 in Q1 2024[21] - The company reported a total profit of ¥84.80 million for Q1 2025, an increase of 9.4% from ¥77.76 million in Q1 2024[20] Cash Flow and Investments - Net cash flow from operating activities decreased significantly by 78.38% to CNY 12,189,916.56, primarily due to a legal dispute affecting funds[8] - Cash flow from operating activities for Q1 2025 was ¥12.19 million, a significant decrease from ¥56.37 million in Q1 2024[24] - Investment activities generated a net cash outflow of ¥7.02 million in Q1 2025, compared to a net inflow of ¥166.56 million in Q1 2024[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,104,121,847.85, a slight decrease of 0.29% from the previous year[5] - As of March 31, 2025, the company's total assets amounted to RMB 6,104,121,847.85, a slight decrease from RMB 6,121,583,989.79 on December 31, 2024[14][16] - The company's cash and cash equivalents increased to RMB 613,367,267.22 from RMB 571,331,157.05, reflecting a growth of approximately 7.4%[14] - Accounts receivable decreased to RMB 985,262,883.67 from RMB 1,014,535,002.51, indicating a decline of about 2.9%[14] - Total current liabilities decreased to RMB 1,485,509,723.58 from RMB 1,584,686,944.92, a reduction of approximately 6.2%[16] - The company's total equity increased to RMB 4,188,258,571.46 from RMB 4,107,966,847.83, representing a growth of about 1.9%[16] - Long-term equity investments rose to RMB 484,016,189.76 from RMB 468,859,304.70, an increase of approximately 3.2%[15] - The company's inventory increased to RMB 862,334,142.48 from RMB 845,762,768.17, reflecting a growth of about 1.9%[14] - The total liabilities decreased to RMB 1,915,863,276.39 from RMB 2,013,617,141.96, a decline of approximately 4.9%[16] - The company's retained earnings increased to RMB 2,133,136,462.81 from RMB 2,056,911,513.83, showing a growth of about 3.7%[16] - The company reported a total current asset of RMB 3,671,257,790.37, slightly down from RMB 3,682,834,689.23[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,369[10] - Major shareholders include Sanda Membrane Technology (Singapore) Co., Ltd. with a 43.60% stake and Qingyuan (China) Co., Ltd. with a 25.81% stake[10] Research and Development - R&D investment totaled CNY 12,174,554.56, accounting for 4.62% of operating revenue, a slight increase from 4.61%[5] Other Financial Metrics - The weighted average return on equity increased by 0.13 percentage points to 1.87%[4] - The company reported non-recurring gains of CNY 7,023,492.66 for the period[7] - Other income for Q1 2025 was ¥64,039.24, a decrease from ¥404,542.12 in Q1 2024[20] - The company experienced a credit impairment loss of ¥10.83 million in Q1 2025, compared to a loss of ¥6.66 million in Q1 2024[19]

Group 1 - The company's revenue for Q1 2025 is 264 million yuan, representing a year-on-year decrease of 7.26% [1] - The company's net profit for Q1 2025 is 76.2249 million yuan, showing a year-on-year increase of 14.20% [1]